Loading...
XNAS
LPTX
Market cap45mUSD
, Last price  
USD
Name

Leap Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:LPTX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
75.46%
Rev. gr., 5y
0.00%
Revenues
0k
000000001,500,0001,500,000000
Net income
-68m
L-17.02%
-7,756,000-18,324,000-25,451,000-21,103,000-25,632,000-29,727,000-23,138,000-32,900,000-27,514,000-40,587,000-54,596,000-81,414,000-67,555,000
CFO
-60m
L+37.82%
-7,550,000-9,939,000-18,017,000-19,580,000-25,337,000-22,137,000-26,033,000-26,902,000-25,957,000-35,157,000-49,044,000-43,753,000-60,299,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
URL
https://www.leaptx.com/
IPO date
Jan 24, 2017
Employees
44
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT